Category: Top Story

MedPal AI plc (LSE:MPAL) has taken another significant step towards becoming one of the UK’s most integrated digital healthcare technology companies with the acquisition of eMARx, a specialist provider of electronic medication administration record (eMAR) software for the UK care home sector.

The acquisition adds a crucial software layer to MedPal’s rapidly expanding healthcare ecosystem, allowing the company to connect every stage of the medication journey, from prescription and robotic dispensing through to bedside administration and AI-powered patient support.

Completing the Healthcare Puzzle

Over the past year, MedPal has been steadily building what it describes as a Health OS, a connected digital platform designed to modernise healthcare delivery.

The business already operates:

• NHS distance-selling pharmacies
• The 23,000 sq ft robotic dispensing facility at Sarus Court
• A growing care home pharmacy business
• New Health, its private healthcare clinic
• Juno, its AI-powered healthcare companion

With the addition of eMARx, MedPal now gains the software platform used directly inside care homes, where every medication administered to residents is digitally verified, recorded and monitored.

This creates what management believes is one of the UK’s only fully integrated medication management platforms.

Entering a Large and Growing Market

The UK has approximately 16,500 care homes supporting more than half a million residents, representing a market worth an estimated £27 billion.

Medication management remains one of the most critical operational challenges within the sector.

Care home residents often take multiple prescriptions each month, while medication errors continue to contribute to avoidable hospital admissions and rising NHS costs.

By combining robotic dispensing, digital medication administration and artificial intelligence, MedPal believes it can help care providers improve patient safety while reducing operational complexity.

High-Quality Recurring Revenue

Beyond the strategic value, eMARx also brings an attractive financial profile.

For the year ending March 2026, the business generated:

• £739,000 revenue
• £106,000 profit after tax
• Approximately 82% gross margins
• A largely recurring software subscription model

Recurring software revenues are highly valued by investors due to their predictability, scalability and attractive margins.

Even more encouraging is that eMARx has approximately tripled revenue over the past three years, demonstrating growing market demand for digital medication management solutions.

Cross-Selling Opportunities

Perhaps the most exciting aspect of the acquisition is the opportunity to expand MedPal’s existing services.

eMARx already serves established care home groups including Care UK, together with numerous independent care providers across Britain.

These relationships create a natural pathway for MedPal to introduce additional services including pharmacy supply, robotic dispensing and AI-driven healthcare support.

Likewise, MedPal’s existing pharmacy customers become ideal candidates for adopting the eMARx platform, creating a powerful cross-selling opportunity that could accelerate growth without the need for significant additional customer acquisition costs.

A Scalable Platform

The acquisition also strengthens utilisation of MedPal’s recently developed robotic dispensing infrastructure.

Management has previously highlighted that Sarus Court was built with significant spare capacity.

By integrating eMARx across more care homes, MedPal can drive increasing prescription volumes through its automated pharmacy operations while maintaining high efficiency and scalability.

This creates operational leverage that could become increasingly valuable as the customer base expands.

Strong Alignment

The transaction structure also aligns the interests of the acquired business with MedPal’s future success.

Rather than being a simple cash acquisition, the majority of the consideration includes MedPal shares that are subject to lock-up arrangements.

Importantly, all seven shareholders of eMARx—including five operational team members, become long-term MedPal shareholders, ensuring continuity, expertise and commitment to future growth.

Looking Ahead

For investors, this acquisition appears to represent more than simply adding another business.

It demonstrates continued execution of a clearly defined strategy to build an integrated healthcare technology platform combining AI, pharmacy automation, software and recurring digital services.

Healthcare continues to undergo rapid digital transformation, while increasing pressure on the NHS and an ageing UK population create long-term structural demand for more efficient medication management solutions.

With the addition of eMARx, MedPal has strengthened both its technology offering and its commercial opportunity, positioning itself to pursue nationwide expansion across one of the UK’s largest healthcare markets.

As MedPal continues executing its Health OS strategy, investors will now be watching closely to see how effectively the company converts this expanded platform into accelerated revenue growth, increased recurring income and greater market penetration across Britain’s care home sector.

For more information visit – https://medpal.co/

Gulf Keystone Petroleum (LSE:GKP) has temporarily suspended production at its Shaikan Field in the Kurdistan Region of Iraq as a precautionary measure following the deterioration in the regional security environment. The decision mirrors actions taken by several other international oil companies operating in the area. Before production was halted, the Shaikan Field had been producing more than 45,000 barrels of oil per day.

The company said its facilities and infrastructure have not been affected by the recent security developments and that it is continuing to monitor the situation closely. While there is no indication of how long the shutdown will remain in place, the suspension highlights the geopolitical risks associated with operating in the region and could affect near-term production levels and revenue until operations resume.

Gulf Keystone continues to benefit from a strong balance sheet and relatively low leverage, providing financial resilience during periods of operational disruption. However, the company’s outlook is tempered by weaker technical indicators, including negative price momentum and a relatively high price-to-earnings ratio. Variability in cash generation, particularly following weaker free cash flow in 2025, also remains a consideration for investors.

More about Gulf Keystone Petroleum

Gulf Keystone Petroleum Ltd. is an independent oil and gas producer focused on the Kurdistan Region of Iraq. The company is listed on both the London Stock Exchange and the Oslo Stock Exchange and is the operator of the Shaikan Field, one of the region’s largest producing oil assets.

The company’s strategy centres on maximising production and value from the Shaikan Field while maintaining operational efficiency and managing the geopolitical risks associated with operating in northern Iraq.

Jadestone Energy (LSE:JSE) has successfully completed and brought online the second well in its 2026 Malaysia infill drilling programme, with the EBA-07ST1 well producing approximately 2,800 barrels of oil per day. The well was drilled around 13% under budget and features a 930-metre horizontal section, reaching a total measured depth of 5,473 metres. It is the longest well drilled at the East Belumut field and has set a new Malaysian record with an extended reach drilling ratio of 4.1.

Combined with the first well in the campaign, which reached peak production of around 3,200 barrels of oil per day, the two wells have increased production at the East Belumut field by more than 150%. Together they have added approximately 6,000 barrels of oil per day, encouraging the company to proceed with a third contingent well. Jadestone believes the results demonstrate the potential to unlock additional reserves from mature fields while supporting higher production, stronger cash generation and increased value across its Asia-Pacific asset portfolio.

Although operational performance continues to improve, the company’s financial outlook remains constrained by negative shareholder equity and relatively high leverage. These challenges are partly offset by stronger operating cash flow, positive technical momentum and a comparatively low price-to-earnings valuation.

More about Jadestone Energy

Jadestone Energy plc is an independent upstream oil and gas company focused on the Asia-Pacific region, with producing assets across Australia, Malaysia, Indonesia and Vietnam. The company specialises in acquiring and optimising mature oil and gas fields, using operational improvements and targeted investment to increase production and extend asset life.

Alongside growing production, Jadestone is expanding its natural gas portfolio and pursuing emissions reductions across its operations. The company has committed to achieving net zero Scope 1 and Scope 2 emissions from its operated assets by 2040 while continuing to invest in existing upstream projects that support long-term energy supply.

MedPal AI plc (LSE:MPAL) has acquired Solid State Technologies Ltd, which trades as eMARx, in a transaction valuing the business at approximately £0.47 million. eMARx provides electronic medication administration record software to UK care homes and pharmacies, and the acquisition adds a recurring, high-margin software business with an established customer base that includes both national care providers and independent operators. The existing eMARx management team will also become long-term shareholders in MedPal AI as part of the transaction.

The acquisition completes the final software component of MedPal’s integrated Health OS platform, linking NHS prescriptions, automated dispensing from the company’s Sarus Court pharmacy hub, medication delivery and barcode-verified administration within care homes. MedPal plans to offer the eMARx platform at little or no cost to care homes that use its pharmacy services exclusively, a strategy designed to accelerate customer adoption, increase pharmacy revenues and improve medication management, safety and oversight for residents, healthcare providers and the NHS across the UK’s £27 billion care home sector.

More about MedPal AI

MedPal AI plc is a UK-based digital healthcare and pharmacy technology company focused on improving medication management across the care home and primary care markets. Its operations include NHS distance-selling pharmacy services, business-to-business pharmacy supply for care homes, a private healthcare clinic and Juno, its AI-powered health assistant.

The company also operates the Sarus Court robotic dispensing hub in Runcorn, which uses BD Rowa automation technology to provide high-volume pharmacy dispensing. By integrating software, pharmacy services and artificial intelligence into a single healthcare platform, MedPal AI aims to streamline the medicines supply chain and strengthen its position in the growing UK care home market.

GSK (LSE:GSK) has announced that the European Medicines Agency has accepted its application to update the prescribing information for Bexsero, seeking approval for a single booster dose for people aged 10 years and older who received the meningococcal B vaccine during infancy. The proposed label expansion is intended to extend protection into adolescence and early adulthood, when cases of invasive meningococcal disease experience a second peak.

The submission is supported by data from a Phase 3b clinical trial demonstrating that a single booster dose successfully restores protective immune responses in individuals aged between 10 and 20 who completed the original vaccination schedule as infants. If the application is approved and adopted by countries with existing meningococcal B immunisation programmes, the booster could help reduce the incidence of invasive meningococcal disease while strengthening GSK’s position in the global vaccine market.

GSK continues to benefit from strong underlying financial performance, supported by healthy operating margins, improving earnings and an attractive valuation, including a relatively low price-to-earnings ratio and a dividend yield of around 3.47%. However, these strengths are partly offset by weaker technical indicators, with the shares trading below key moving averages, as well as financial considerations including leverage and variable free cash flow generation.

More about GSK

GSK is a global biopharmaceutical company focused on developing innovative vaccines and medicines to prevent and treat disease. The company combines scientific research, advanced technology and global manufacturing capabilities to address a broad range of infectious diseases and chronic health conditions.

Its vaccine portfolio includes Bexsero, a meningococcal B vaccine approved in 61 countries and incorporated into several national immunisation programmes across Europe. Since its launch in 2015, approximately 138 million doses of Bexsero have been distributed worldwide, making it one of the leading vaccines for the prevention of meningococcal B disease.

The International Energy Agency (IEA) has warned that the world has only a matter of weeks to avoid broader economic consequences if shipping through the Strait of Hormuz is not fully restored.

Escalating tensions in the Middle East have once again disrupted tanker traffic through the critical maritime corridor, increasing concerns over global energy supplies and inflation.

Shipping Disruptions Push Oil Prices Higher

Recent attacks on commercial vessels, combined with renewed U.S. military action and restrictions on Iranian oil exports, have brought tanker movements through the Strait of Hormuz to a standstill after a brief recovery.

The slowdown has halted efforts by Gulf producers to accelerate exports, while oil prices have risen roughly 13% since last Friday as markets price in higher geopolitical risk.

Markets Monitor Inflation and Energy Risks

Investors are increasingly concerned that extended shipping disruptions could tighten fuel supplies and push inflation higher, prompting renewed volatility across financial markets.

According to analysts, refined fuel markets are currently under greater strain than crude oil supplies.

IEA Calls for Immediate Reopening

Fatih Birol warned that the economic consequences could emerge quickly if shipping is not restored.

“If the Strait of Hormuz remains closed we may again have some difficulty for global economies, including those in the region and developing nations and Asia,” he said.

“It is not months, it is weeks” after which the strait needs to be “fully open, unconditionally open,” to spare the global economy from new challenges and slowdown.

The IMO also cautioned that the waterway has become too dangerous for many commercial vessels, underscoring the growing risks to global energy trade.

Hedge funds have endured one of their toughest trading stretches in almost a year as crowded artificial intelligence and technology positions reversed amid elevated market volatility.

Quantitative investment firms suffered the sharpest declines, while traditional equity managers also cut exposure to AI-linked trades as investors reduced risk across global markets.

Quant Strategies Lose Momentum

Algorithm-driven hedge funds have surrendered around one-quarter of their gains for 2026, with year-to-date returns falling from 14.4% to 10.8%.

The losses were driven largely by positions involving U.S. equities, developed Asian markets and European stocks, all of which experienced significant price swings.

Semiconductor Volatility Adds Pressure

Trading conditions became increasingly difficult as semiconductor stocks experienced sharp fluctuations during late June and early July. High levels of leverage among investors in South Korea further amplified market moves.

Quantitative managers represented roughly 10% of the largest hedge funds globally in 2025, underscoring their growing role in financial markets.

Regulators Highlight Financial Stability Concerns

Authorities including the Bank of England, the Bank of Japan and the Bank for International Settlements have continued to warn that elevated asset valuations and expanding hedge fund participation could increase financial market volatility.

AI Positions Unwind Across the Industry

Fundamental hedge funds declined 2.2% over the same period as previously popular AI investments lost momentum.

Portfolio managers “aggressively” reduced AI-related holdings, driving hedge fund leverage to its lowest level in the past year as firms sought to lower overall market exposure.

The U.S. Energy Information Administration (EIA) reported that commercial crude oil inventories declined by 1.7 million barrels during the week ending July 10, reducing total stockpiles to 409.7 million barrels. The latest figures leave U.S. crude inventories 6% below the five-year seasonal average as investors continue monitoring developments in global energy markets.

The government report came after the American Petroleum Institute (API) estimated a smaller draw of 564,000 barrels in its preliminary weekly inventory data.

Crude Prices Slip Even With Rising Middle East Tensions

Despite heightened geopolitical concerns involving the United States and Iran, oil prices traded lower on Wednesday morning. Brent crude changed hands at $84.08 per barrel at 10:45 a.m. in New York, down $0.65 (0.77%) on the session but still around $7 per barrel above last week’s level. WTI crude fell $0.21 (0.26%) to $79.13 per barrel.

Mixed Fuel Inventory Trends Continue

According to the EIA, gasoline inventories declined by 1.5 million barrels, while gasoline production eased to an average of 9.6 million barrels per day.

Distillate fuel inventories, however, climbed by 4.6 million barrels as production increased to an average of 5.3 million barrels per day. Even with the latest increase, distillate inventories remain 11% below the five-year seasonal average.

Petroleum Demand Remains Resilient

The report also indicated that total petroleum products supplied averaged 20.3 million barrels per day over the past four weeks, up 0.3% from the same period last year.

Average gasoline supplied reached 8.9 million barrels per day, while distillate supplied averaged 3.7 million barrels per day, representing a 2.1% decline compared with a year ago.